- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01270347
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)
Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will assess the comparative safety of MP-376 (Aeroquin) and Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals] over three consecutive cycles of 28-days treatment followed by 28-days off in stable CF patients with chronic P. aeruginosa lung infection. Efficacy data for MP-376 and TIS at the end of the first 28-day treatment period will also be compared, as well as explored over multiple treatment cycles.
Study patients participating in Mpex 209 will be given the option to participate in a six-month open label extension phase of the Mpex 209 protocol. The open label extension will allow enrolled patients to receive three additional courses of MP-376 (levofloxacin inhalation solution, Aeroquin™).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Hôpital Pellegrin Enfants - CHU Bordeaux
-
Montpellier, France, 34295
- CRCM adultes et enfants Service des maladies respiratoires et pédiatrie 1 CHU- Arnaud de Villeneuve
-
Paris, France, 75014
- Hopital Cochin
-
Paris, France, 75743
- Hôpital Necker-Enfants Malades
-
Pessac, France, 33604
- Hôpital Haut-Lévêque CHU de Bordeaux
-
Toulouse, France, 31059
- CRCM adulte Hôpital Larrey-CHU de Toulouse
-
-
-
-
-
Berlin, Germany
- Charité Campus Virchow-Klinikum
-
Dresden, Germany
- Universitätskinderklinik Dresden Mukoviszidose-Ambulanz
-
Essen, Germany
- Universitatsklinikum Essen
-
Frankfurt, Germany
- Universitatsklinikum Frankfurt
-
Frankfurt, Germany
- Katharina-Kasper Kliniken GmbH St. Elisabethen-Krankenhaus Medizinische Klinik
-
Gieben, Germany
- Universitätsklinik Gießen und Marburg GmbH Zentrum für Kinderheilkunde und Jugendmedizin
-
Hamburg, Germany
- Kinderärztliche Gemeinschaftspraxis Dr. H. E. Heuer, Dr. C. Runge, W. Sextro
-
Kiel, Germany
- Universitätsklinikum Kiel
-
Munchen, Germany
- Ludwig-Maximilians Universität Klinikum Innenstadt
-
Munich, Germany
- Dr. von Haunersches Kinderspital der Universität München Christiane Herzog Ambulanz
-
Tubingen, Germany
- Universitätsklinik für Kinder- und Jugendmedizin
-
-
-
-
-
Cork, Ireland
- Cork University Hospital
-
Dublin, Ireland
- Beaumont Hospital
-
Dublin, Ireland
- St. Vincent's University Hospital
-
Dublin, Ireland
- National Children's Hospital Tallaght
-
-
-
-
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Jerusalem, Israel, 91240
- Hadassah Medical Center Mount Scopus
-
Petah Tikva, Israel, 49202
- Schneider Childrens Medical Center of Israel
-
Ramat Gan, Israel, 52621
- Safra Childrens Hospital, Sheba Medical Center
-
-
-
-
-
Belfast, United Kingdom, BT9 7AB
- Belfast City Hospital
-
Birmingham, United Kingdom, B95SS
- Birmingham Heartlands Hospital
-
Cottingham, United Kingdom, HU16 5JQ
- Castle Hill Hospital
-
Leeds, United Kingdom, LS97TF
- St James's University Hospital
-
London, United Kingdom, SE59RS
- King's College Hospital
-
Penarth, United Kingdom, CF64 2XX
- University Hospital Llandough, Penarth
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
-
Tucson, Arizona, United States, 85724
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
-
-
California
-
La Jolla, California, United States, 92037
-
Long Beach, California, United States, 90806
-
Los Angeles, California, United States, 90033
-
Los Angeles, California, United States, 90027
- Childrens Hospital
-
Oakland, California, United States, 94611
-
Orange, California, United States, 92868
-
Palo Alto, California, United States, 94304
-
Sacramento, California, United States, 95817
-
San Diego, California, United States, 92103
-
San Diego, California, United States, 92123
-
San Francisco, California, United States, 94115
-
-
Colorado
-
Aurora, Colorado, United States, 80045
-
Denver, Colorado, United States, 80206
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
-
New Haven, Connecticut, United States, 65020
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
-
-
Florida
-
Gainesville, Florida, United States, 32610
-
Jacksonville, Florida, United States, 32207
-
Miami, Florida, United States, 33136
-
Orlando, Florida, United States, 32801
-
Saint Petersburg, Florida, United States, 33701
-
Tampa, Florida, United States, 33606
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
-
-
Idaho
-
Boise, Idaho, United States, 83712
-
-
Illinois
-
Chicago, Illinois, United States, 60637
-
Chicago, Illinois, United States, 60614
-
Glenview, Illinois, United States, 60025
-
Niles, Illinois, United States, 60714
-
Peoria, Illinois, United States, 61637
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
-
Indianapolis, Indiana, United States, 43202
-
-
Kansas
-
Wichita, Kansas, United States, 67214
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
-
Louisville, Kentucky, United States, 40202
-
-
Maine
-
Portland, Maine, United States, 04102
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
-
Boston, Massachusetts, United States, 02115
-
Worcester, Massachusetts, United States, 01655
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
-
Detroit, Michigan, United States, 48201
-
Grand Rapids, Michigan, United States, 49503
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
-
-
Missouri
-
Columbia, Missouri, United States, 65212
-
Kansas City, Missouri, United States, 64108
-
Saint Louis, Missouri, United States, 63110
-
-
Nebraska
-
Omaha, Nebraska, United States, 68105
-
-
Nevada
-
Las Vegas, Nevada, United States, 89107
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
-
Manchester, New Hampshire, United States, 03104
-
-
New Jersey
-
Livingston, New Jersey, United States, 07039
-
Morristown, New Jersey, United States, 07962
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
-
-
New York
-
Albany, New York, United States, 12208
-
Albany, New York, United States, 12208
- Albany Medical College #2
-
New Hyde Park, New York, United States, 11042
-
New York, New York, United States, 10032
-
New York, New York, United States, 10003
-
Syracuse, New York, United States, 13210
-
Valhalla, New York, United States, 10595
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
-
-
Ohio
-
Akron, Ohio, United States, 44308
-
Cincinnati, Ohio, United States, 45229
-
Columbus, Ohio, United States, 43205
-
Dayton, Ohio, United States, 45404
-
Toledo, Ohio, United States, 43606
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma CF Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
-
Philadelphia, Pennsylvania, United States, 19104
-
Philadelphia, Pennsylvania, United States, 19102
-
Pittsburgh, Pennsylvania, United States, 15224
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
-
Columbia, South Carolina, United States, 29203
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
-
Nashville, Tennessee, United States, 37232
-
-
Texas
-
Austin, Texas, United States, 78723
-
Dallas, Texas, United States, 75390
-
Fort Worth, Texas, United States, 76104
-
Houston, Texas, United States, 77030
-
San Antonio, Texas, United States, 78212
-
Tyler, Texas, United States, 75708
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
-
-
Vermont
-
Colchester, Vermont, United States, 05446
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
-
Norfolk, Virginia, United States, 23507
-
Portsmouth, Virginia, United States, 23708
-
Richmond, Virginia, United States, 23298
-
-
Washington
-
Seattle, Washington, United States, 98105
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53201
-
Milwaukee, Wisconsin, United States, 53266
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (selected):
- > 12 years of age
- Confirmed Diagnosis of Cystic Fibrosis
- Positive sputum culture for P. aeruginosa within the past 12 months
- Patients are able to elicit an FEV1 >/= 25% but </= 85% of predicted value at screening
- Have received at least 3 courses of inhaled tobramycin over the preceding 12 months
- Clinically stable with no changes in health status within the last 28 days
- Able to reproducibly produce sputum and perform spirometry
Exclusion Criteria (selected):
- Use of any nebulized or systemic antibiotics within 28 days prior to baseline
- History of hypersensitivity to fluoroquinolones or inhaled or systemic aminoglycosides including tobramycin or any excipients
- Evidence of acute upper within 10 days or lower respiratory infections within 28 days prior to dosing
- CrCl < 20 at Screening
- History of lung transplantation
Extension Portion of the Study: Patients enrolled in Mpex 209 are permitted to participate in the open label extension as long as they complete Visit 7 (Day 168), provide informed consent for participation in the open label extension of in the study and are clinically stable, as assessed by the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Aeroquin
Aeroquin, Inhaled Levofloxacin (MP-376)
|
MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
Other Names:
|
ACTIVE_COMPARATOR: TIS
Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals]
|
Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 168 and 336 days
|
Assessment of adverse events and safety from Baseline through Final Visit Extension portion of Study: Descriptive statistics for all patients receiving at least one dose of MP-376 in the extension phase of the study will be summarized for the safety, microbiology, and disease-related endpoints. No formal hypothesis tests are planned. |
168 and 336 days
|
Efficacy
Time Frame: 28 Days
|
Percent change in percent predicted FEV1 from Baseline to Day 28
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in respiratory and other domains of CFQ-R from Baseline to Day 28
Time Frame: 28 days
|
28 days
|
Evaluate changes in FEV1 and FVC from Baseline to Day 28
Time Frame: 28 days
|
28 days
|
Changes in bacterial load and susceptability patterns of isolated organisms from Baseline to Day 28
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Fibrosis
- Cystic Fibrosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Pharmaceutical Solutions
- Levofloxacin
- Ofloxacin
- Tobramycin
Other Study ID Numbers
- Mpex-209
- 2010-019634-26 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on MP-376 (Levofloxacin Solution for Inhalation)
-
Horizon Pharma USA, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Horizon Pharma USA, Inc.CompletedCystic FibrosisUnited States
-
Horizon Pharma USA, Inc.Forest LaboratoriesCompletedCystic FibrosisUnited States, Australia, Israel, New Zealand, Canada
-
Horizon Pharma USA, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Horizon Pharma USA, Inc.CompletedCystic FibrosisUnited States
-
Horizon Pharma USA, Inc.CompletedCystic Fibrosis (CF)Germany, United States, Netherlands
-
Erik Allen JensenUniversity of FloridaActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedAcute Viral BronchiolitisFrance
-
Children's Hospital of PhiladelphiaCompletedSaline Solution, Hypertonic | Bronchiolitis, ViralUnited States
-
Apeptico Forschung und Entwicklung GmbHRecruiting